Drug Trial Radar · NCT01076582
Comparative Trial in Hormone Withdrawal Associated Symptoms
Last checked: Nov 20, 2026Latest source record: Oct 28, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
592
Actual
Start
Apr 2010
Primary completion
Oct 2011
Study completion Oct 2011
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Feb 26, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical research study will examine whether an oral contraceptive pill taken with a monthly hormone-free interval of 4 days reduces hormone withdrawal associated symptoms compared to an oral contraceptive pill taken with a monthly hormone-free interval of 7 days after 4 cycles of treatment.
Conditions
- Oral Contraceptive
Interventions
EE20/DRSP (YAZ, BAY86-5300)Drug
4 cycles of treatment / per cycle: 1 tablet (EE 0.02 mg / DRSP 3 mg) daily for 24 days followed by 1 placebo tablet daily for 4 days
Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon)Drug
4 cycles of treatment / per cycle: 1 tablet (EE 0.02 mg / DSG 0.15 mg) daily for 21 days followed by 1 placebo tablet daily for 7 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline to cycle 4 in the sum of composite score during cycle days 22 - 28. The composite score comprises headache, pelvic pain and bloating (each measured by 7-point Likert scales).Time frame: Cycle days 22 - 28 of baseline cycle and cycle 4.
Locations
44 sites in 14 countries. Site status is shown where the registry gives one.
Site not named
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Site not named
Rosario, Santa Fe Province, Argentina
Site not named
Santiago, Chile
Site not named
Santiago, Chile
Site not named
Temuco, Chile
Site not named
Santiago, Santiago Metropolitan, Chile
Site not named
Santiago, Santiago Metropolitan, Chile
Site not named
Bogotá, Colombia
Site not named
Medellín, Colombia
Site not named
Bucaramanga, Santander Department, Colombia
Site not named
Brno, Czechia
Site not named
Prague, Czechia
Site not named
Tábor, Czechia
Site not named
Heidelberg, Baden-Wurttemberg, Germany
Site not named
Fürth, Bavaria, Germany
Site not named
Hanover, Lower Saxony, Germany
Site not named
Leipzig, Saxony, Germany
Site not named
Magdeburg, Saxony-Anhalt, Germany
Site not named
Jena, Thuringia, Germany
Site not named
Florence, Italy
Site not named
Milan, Italy
Site not named
Siena, Italy
Site not named
Manila, Philippines
Site not named
Pasig, Philippines
Site not named
Coimbra, Portugal
Site not named
Porto, Portugal
Site not named
Lisbon, Lisbon District, Portugal
Site not named
Moscow, Russia
Site not named
Moscow, Russia
Site not named
Moscow, Russia
Site not named
Seoul, South Korea
Site not named
Seoul, South Korea
Site not named
Seoul, Korea, South Korea
Site not named
Seoul, Korea, South Korea
Site not named
Basel, Canton of Basel-City, Switzerland
Site not named
Bern, Canton of Bern, Switzerland
Site not named
Sankt Gallen, Canton of St. Gallen, Switzerland
Site not named
Bangkok, Thailand
Site not named
Bangkok, Thailand, Thailand
Site not named
Songkhla, Thailand, Thailand
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.